Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Locoregional Therapy for Hepatocellular Carcinoma.

Literature DB >> 26674459

Locoregional Therapy for Hepatocellular Carcinoma.

M Kudo.

Abstract

Entities: Disease

Year: 2015 PMID： 26674459 PMCID： PMC4608615 DOI： 10.1159/000367741

Source DB: PubMed Journal: Liver Cancer ISSN： 1664-5553 Impact factor: 11.740

× No keyword cloud information.

10 in total

1. Surgical and Locoregional Therapy of HCC: TACE.

Authors: Masakatsu Tsurusaki; Takamichi Murakami
Journal: Liver Cancer Date: 2015-07-10 Impact factor: 11.740

Review 2. Current Status of Hepatic Arterial Infusion Chemotherapy.

Authors: Shuntaro Obi; Shinpei Sato; Toshihiro Kawai
Journal: Liver Cancer Date: 2015-08-12 Impact factor: 11.740

3. Clinical Practice Guidelines for Hepatocellular Carcinoma Differ between Japan, United States, and Europe.

Authors:
Journal: Liver Cancer Date: 2015-03 Impact factor: 11.740

4. Management of hepatocellular carcinoma in Japan: Consensus-Based Clinical Practice Guidelines proposed by the Japan Society of Hepatology (JSH) 2010 updated version.

Authors: Masatoshi Kudo; Namiki Izumi; Norihiro Kokudo; Osamu Matsui; Michiie Sakamoto; Osamu Nakashima; Masamichi Kojiro; Masatoshi Makuuchi
Journal: Dig Dis Date: 2011-08-09 Impact factor: 2.404

Review 5. Local ablation for hepatocellular carcinoma in taiwan.

Authors: Shi-Ming Lin
Journal: Liver Cancer Date: 2013-04 Impact factor: 11.740

6. Insufficient ablative margin determined by early computed tomography may predict the recurrence of hepatocellular carcinoma after radiofrequency ablation.

Authors: Wei Teng; Ka-Wai Liu; Chen-Chun Lin; Wen-Juei Jeng; Wei-Ting Chen; I-Shyan Sheen; Chun-Yen Lin; Shi-Ming Lin
Journal: Liver Cancer Date: 2015-03 Impact factor: 11.740

Review 7. Radiotherapeutic options for hepatocellular carcinoma with portal vein tumor thrombosis.

Authors: Dong Soo Lee; Jinsil Seong
Journal: Liver Cancer Date: 2014-03 Impact factor: 11.740

Review 8. JSH Consensus-Based Clinical Practice Guidelines for the Management of Hepatocellular Carcinoma: 2014 Update by the Liver Cancer Study Group of Japan.

Authors: Masatoshi Kudo; Osamu Matsui; Namiki Izumi; Hiroko Iijima; Masumi Kadoya; Yasuharu Imai; Takuji Okusaka; Shiro Miyayama; Kaoru Tsuchiya; Kazuomi Ueshima; Atsushi Hiraoka; Masafumi Ikeda; Sadahisa Ogasawara; Tatsuya Yamashita; Tetsuya Minami; Koichiro Yamakado
Journal: Liver Cancer Date: 2014-10 Impact factor: 11.740

Review 9. Recent Advances in Tumor Ablation for Hepatocellular Carcinoma.

Authors: Tae Wook Kang; Hyunchul Rhim
Journal: Liver Cancer Date: 2015-07-17 Impact factor: 11.740

10. Management of hepatocellular carcinoma: an update.

Authors: Jordi Bruix; Morris Sherman
Journal: Hepatology Date: 2011-03 Impact factor: 17.425

10 in total

12 in total

5. Regorafenib as Second-Line Systemic Therapy May Change the Treatment Strategy and Management Paradigm for Hepatocellular Carcinoma.

Authors: M Kudo
Journal: Liver Cancer Date: 2016-09-14 Impact factor: 11.740

Locoregional Therapy for Hepatocellular Carcinoma.

1. Surgical and Locoregional Therapy of HCC: TACE.

Review 2. Current Status of Hepatic Arterial Infusion Chemotherapy.

3. Clinical Practice Guidelines for Hepatocellular Carcinoma Differ between Japan, United States, and Europe.

4. Management of hepatocellular carcinoma in Japan: Consensus-Based Clinical Practice Guidelines proposed by the Japan Society of Hepatology (JSH) 2010 updated version.

Review 5. Local ablation for hepatocellular carcinoma in taiwan.

6. Insufficient ablative margin determined by early computed tomography may predict the recurrence of hepatocellular carcinoma after radiofrequency ablation.

Review 7. Radiotherapeutic options for hepatocellular carcinoma with portal vein tumor thrombosis.

Review 8. JSH Consensus-Based Clinical Practice Guidelines for the Management of Hepatocellular Carcinoma: 2014 Update by the Liver Cancer Study Group of Japan.

Review 9. Recent Advances in Tumor Ablation for Hepatocellular Carcinoma.

10. Management of hepatocellular carcinoma: an update.

1. Immune Checkpoint Blockade in Hepatocellular Carcinoma.

2. A New Era of Systemic Therapy for Hepatocellular Carcinoma with Regorafenib and Lenvatinib.

3. Albumin-Bilirubin Grade and Hepatocellular Carcinoma Treatment Algorithm.

4. Immune Checkpoint Blockade in Hepatocellular Carcinoma: 2017 Update.

5. Regorafenib as Second-Line Systemic Therapy May Change the Treatment Strategy and Management Paradigm for Hepatocellular Carcinoma.

6. Breakthrough Imaging in Hepatocellular Carcinoma.

7. Defect Reperfusion Imaging with Sonazoid®: A Breakthrough in Hepatocellular Carcinoma.

8. Heterogeneity and Subclassification of Barcelona Clinic Liver Cancer Stage B.

9. Molecular Targeted Therapy for Hepatocellular Carcinoma: Where Are We Now?

Review 10. Extrahepatic Applications of Yttrium-90 Radioembolization.